Last reviewed · How we verify

Ibuprofen + Paracetamol + Codeine

Ullevaal University Hospital · FDA-approved active Small molecule

This combination reduces pain and fever through inhibition of prostaglandin synthesis (ibuprofen and paracetamol) while codeine provides additional analgesia via opioid receptor agonism.

This combination reduces pain and fever through inhibition of prostaglandin synthesis (ibuprofen and paracetamol) while codeine provides additional analgesia via opioid receptor agonism. Used for Moderate acute pain, Post-operative pain, Musculoskeletal pain.

At a glance

Generic nameIbuprofen + Paracetamol + Codeine
Also known asIbuprofen, ATC code: M01A E01, Paracetamol (Acetaminophen), ATC code: N02B E01, Codeine
SponsorUllevaal University Hospital
Drug classCombination analgesic (NSAID + acetaminophen + opioid)
TargetCOX-1/COX-2 (ibuprofen, paracetamol); mu opioid receptor (codeine)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Ibuprofen and paracetamol are nonsteroidal anti-inflammatory drugs and analgesics that inhibit cyclooxygenase enzymes to reduce prostaglandin production, thereby decreasing pain and fever. Codeine is a weak opioid agonist that binds to mu opioid receptors in the central nervous system to enhance pain relief. The combination provides synergistic analgesic effects for moderate pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: